JP2020526520A5 - - Google Patents
Info
- Publication number
- JP2020526520A5 JP2020526520A5 JP2020500206A JP2020500206A JP2020526520A5 JP 2020526520 A5 JP2020526520 A5 JP 2020526520A5 JP 2020500206 A JP2020500206 A JP 2020500206A JP 2020500206 A JP2020500206 A JP 2020500206A JP 2020526520 A5 JP2020526520 A5 JP 2020526520A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- free base
- fluoroquinoline
- cyclohexyl
- chlorophenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762527855P | 2017-06-30 | 2017-06-30 | |
| US62/527,855 | 2017-06-30 | ||
| PCT/US2018/040262 WO2019006283A1 (en) | 2017-06-30 | 2018-06-29 | AMORPHOUS AND CRYSTALLINE FORMS OF IDO INHIBITORS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020526520A JP2020526520A (ja) | 2020-08-31 |
| JP2020526520A5 true JP2020526520A5 (enExample) | 2025-03-14 |
| JP7690284B2 JP7690284B2 (ja) | 2025-06-10 |
Family
ID=64742242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020500206A Active JP7690284B2 (ja) | 2017-06-30 | 2018-06-29 | Ｉｄｏ阻害剤の非晶質形態および結晶形態 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11236049B2 (enExample) |
| EP (1) | EP3644993B1 (enExample) |
| JP (1) | JP7690284B2 (enExample) |
| KR (1) | KR102630575B1 (enExample) |
| CN (1) | CN111093651B (enExample) |
| AU (1) | AU2018294314B2 (enExample) |
| CA (1) | CA3066789A1 (enExample) |
| EA (1) | EA202090119A1 (enExample) |
| IL (1) | IL271601B2 (enExample) |
| MX (2) | MX391848B (enExample) |
| SG (1) | SG11201911937UA (enExample) |
| WO (1) | WO2019006283A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019006292A1 (en) * | 2017-06-30 | 2019-01-03 | Bristol-Myers Squibb Company | SUBSTITUTED QUINOLINYCYCLOHEXYLPROPANAMIDE COMPOUNDS AND IMPROVED PROCESSES FOR THE PREPARATION THEREOF |
| EP3711387B1 (en) * | 2017-11-17 | 2024-06-26 | Telefonaktiebolaget LM Ericsson (publ) | Signaling ta-offset in nr |
| CN110357813A (zh) * | 2018-04-09 | 2019-10-22 | 信达生物制药(苏州)有限公司 | 一种新型吲哚胺2,3-双加氧酶抑制剂及其制备方法和用途 |
| CN110869351B (zh) | 2018-06-27 | 2022-03-18 | 深圳仁泰医药科技有限公司 | (r)-n-(4-氯苯基)-2-(顺-4-(6-氟喹啉-4-基)环己基)丙酰胺的晶型 |
| CN114641278A (zh) * | 2019-09-11 | 2022-06-17 | 百时美施贵宝公司 | 吲哚胺2,3-双加氧酶抑制剂的药物配制品 |
| CA3159071A1 (en) * | 2019-11-26 | 2021-06-03 | Tamar I. ROSENBAUM | Salts/cocrystals of (r)-n-(4-chlorophenyl)-2-((1s,4s)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide |
| AR120935A1 (es) * | 2020-01-02 | 2022-03-30 | Hutchison Medipharma Ltd | Derivados de amida y usos de los mismos |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6627646B2 (en) * | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| JP5238936B2 (ja) | 2005-03-25 | 2013-07-17 | ジーアイティーアール，インク． | Ｇｉｔｒ結合分子およびその使用 |
| DK1879573T3 (da) | 2005-05-10 | 2013-02-25 | Incyte Corp | Modulatorer af indolamin 2,3-dioxygenase og fremgangsmåder til anvendelse deraf |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| ES2540561T3 (es) | 2005-12-20 | 2015-07-10 | Incyte Corporation | N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| CA2663057C (en) | 2006-09-19 | 2015-12-08 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| PT2175884T (pt) | 2007-07-12 | 2016-09-21 | Gitr Inc | Terapias de combinação empregando moléculas de ligação a gitr |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| WO2009073620A2 (en) | 2007-11-30 | 2009-06-11 | Newlink Genetics | Ido inhibitors |
| EP2296789A1 (fr) | 2008-05-29 | 2011-03-23 | Saint-Gobain Centre de Recherches et d'Etudes Européen | Structure en nid d'abeille a base de titanate d'aluminium |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| IN2015DN02826A (enExample) | 2009-09-03 | 2015-09-11 | Merck Sharp & Dohme | |
| EP2493862B1 (en) | 2009-10-28 | 2016-10-05 | Newlink Genetics Corporation | Imidazole derivatives as ido inhibitors |
| DK2510010T3 (en) | 2009-12-10 | 2015-12-14 | Hoffmann La Roche | Antibodies that bind to human CSF1R extracellular domain 4 and their use |
| DK2542256T3 (da) | 2010-03-04 | 2019-08-26 | Macrogenics Inc | Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf |
| CN102918061B (zh) | 2010-03-05 | 2016-06-08 | 霍夫曼-拉罗奇有限公司 | 针对人csf-1r的抗体及其用途 |
| RU2617971C2 (ru) | 2010-03-05 | 2017-04-28 | Ф.Хоффманн-Ля Рош Аг | Антитела против csf-1r человека и их применение |
| EP3943154A1 (en) | 2010-05-04 | 2022-01-26 | Five Prime Therapeutics, Inc. | Antibodies that bind csf1r |
| NZ729044A (en) | 2010-09-09 | 2020-07-31 | Pfizer | 4-1bb binding molecules |
| NO2694640T3 (enExample) | 2011-04-15 | 2018-03-17 | ||
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| MX356337B (es) | 2011-12-15 | 2018-05-23 | Hoffmann La Roche | Anticuerpos contra csf-1r humano y sus usos. |
| MX2014008961A (es) | 2012-02-06 | 2014-10-14 | Genentech Inc | Composiciones y metodos para utilizar inhibidores de csf1r. |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| KR20150018533A (ko) | 2012-05-11 | 2015-02-23 | 파이브 프라임 테라퓨틱스, 인크. | 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법 |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| UY36390A (es) * | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen |
| AR102537A1 (es) | 2014-11-05 | 2017-03-08 | Flexus Biosciences Inc | Agentes inmunomoduladores |
| WO2019006292A1 (en) | 2017-06-30 | 2019-01-03 | Bristol-Myers Squibb Company | SUBSTITUTED QUINOLINYCYCLOHEXYLPROPANAMIDE COMPOUNDS AND IMPROVED PROCESSES FOR THE PREPARATION THEREOF |
-
2018
- 2018-06-29 KR KR1020207002491A patent/KR102630575B1/ko active Active
- 2018-06-29 MX MX2019014885A patent/MX391848B/es unknown
- 2018-06-29 JP JP2020500206A patent/JP7690284B2/ja active Active
- 2018-06-29 AU AU2018294314A patent/AU2018294314B2/en active Active
- 2018-06-29 US US16/624,490 patent/US11236049B2/en active Active
- 2018-06-29 EA EA202090119A patent/EA202090119A1/ru unknown
- 2018-06-29 CA CA3066789A patent/CA3066789A1/en active Pending
- 2018-06-29 EP EP18823337.3A patent/EP3644993B1/en active Active
- 2018-06-29 SG SG11201911937UA patent/SG11201911937UA/en unknown
- 2018-06-29 WO PCT/US2018/040262 patent/WO2019006283A1/en not_active Ceased
- 2018-06-29 IL IL271601A patent/IL271601B2/en unknown
- 2018-06-29 CN CN201880044036.6A patent/CN111093651B/zh active Active
-
2019
- 2019-12-10 MX MX2021015656A patent/MX2021015656A/es unknown
-
2021
- 2021-12-16 US US17/553,434 patent/US12421195B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7690284B2 (ja) | Ｉｄｏ阻害剤の非晶質形態および結晶形態 | |
| US11104682B2 (en) | Salts of TAM inhibitors | |
| TW202114680A (zh) | Ｈｐｋ１抑制劑之固體形式 | |
| US12173006B2 (en) | Crystalline forms of a phosphoinositide 3-kinase (PI3K) inhibitor | |
| WO2023122777A1 (en) | Oxime derivatives useful as t cell activators | |
| TW202023562A (zh) | 喹唑啉化合物及其鹽酸鹽之結晶形態 | |
| AU2024314878A1 (en) | Substituted oxoisoindolinyl piperidine-2,6-dione compound as anticancer agent | |
| AU2024285766A1 (en) | Spirocyclic substituted oxoisoindolinyl piperidine-2,6-dione compound | |
| KR20250019700A (ko) | 치환된 페닐 옥사졸론 화합물 | |
| US12527783B2 (en) | Salts/cocrystals of (R)-N-(4-chlorophenyl-2-((1S,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide | |
| EA041037B1 (ru) | Аморфные и кристаллические формы ido-ингибиторов | |
| EA049146B1 (ru) | Аморфные и кристаллические формы ido-ингибиторов | |
| BR112019027259B1 (pt) | Formas amorfas e cristalinas de inibidores da ido, seus usos, e composição farmacêutica | |
| HK40127606A (en) | Substituted phenyl oxazolone compounds |